Cargando…

Chronotolerance study of the antiepileptic drug valproic acid in mice

BACKGROUND: Valproic acid (VPA) is an antiepileptic drug widely used for the treatment of absence seizures and generalized tonic-clonic seizures. The present work aims to study whether VPA-induced toxicity varies according to the dosing-time in the 24 hour-scale. METHODS: The influence of dosing-tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Cherif, Wafa, Dridi, Ichrak, Aouam, Karim, Ben-Attia, Mossadok, Reinberg, Alain, Boughattas, Naceur A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431278/
https://www.ncbi.nlm.nih.gov/pubmed/22574933
http://dx.doi.org/10.1186/1740-3391-10-3
_version_ 1782242054123814912
author Ben-Cherif, Wafa
Dridi, Ichrak
Aouam, Karim
Ben-Attia, Mossadok
Reinberg, Alain
Boughattas, Naceur A
author_facet Ben-Cherif, Wafa
Dridi, Ichrak
Aouam, Karim
Ben-Attia, Mossadok
Reinberg, Alain
Boughattas, Naceur A
author_sort Ben-Cherif, Wafa
collection PubMed
description BACKGROUND: Valproic acid (VPA) is an antiepileptic drug widely used for the treatment of absence seizures and generalized tonic-clonic seizures. The present work aims to study whether VPA-induced toxicity varies according to the dosing-time in the 24 hour-scale. METHODS: The influence of dosing-time on tolerance to VPA was investigated in 120 male Swiss mice synchronized under a light-dark cycle (12:12). The mean VPA lethal dose was first determined to be 850 ± 0.2 mg/kg, i.p.. Such a dose was administered by i.p. route to a total of 90 mice divided in six circadian stages [1, 5, 9, 13, 17 and 21 Hours After Light Onset (HALO)] (15 mice/circadian time); 30 mice were used as control (5 mice / circadian time). RESULTS: The surviving treated mice exhibited a significant circadian variation in rectal temperature and body weight loss (p < 0.001). The least rectal temperature change and body weight loss occurred when VPA was injected at 9 HALO. Drug dosing at 9 HALO resulted in -9 % weight loss whereas drug dosing at 17 HALO was -15 % (Ø = 20.3 HALO ± 1.1 h, p ≤ 0.0001). Lethal toxicity also varied according to circadian dosing-time (χ(2) = 42.1, p < 0.0001). The highest (60 %) and the lowest (6.67 %) survival rates were observed at 9 HALO and 17 HALO respectively. Cosinor analyses validated a significant circadian rhythm in survival duration with an acrophase at 8.4 HALO ± 0.75 h (p < 0.001). CONCLUSIONS: With regards to these data the optimal tolerance to VPA occurred when the drug was administered in the second half of the light-rest span of mice which is physiologically analogous to the second half of the night for human patients.
format Online
Article
Text
id pubmed-3431278
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34312782012-08-31 Chronotolerance study of the antiepileptic drug valproic acid in mice Ben-Cherif, Wafa Dridi, Ichrak Aouam, Karim Ben-Attia, Mossadok Reinberg, Alain Boughattas, Naceur A J Circadian Rhythms Research BACKGROUND: Valproic acid (VPA) is an antiepileptic drug widely used for the treatment of absence seizures and generalized tonic-clonic seizures. The present work aims to study whether VPA-induced toxicity varies according to the dosing-time in the 24 hour-scale. METHODS: The influence of dosing-time on tolerance to VPA was investigated in 120 male Swiss mice synchronized under a light-dark cycle (12:12). The mean VPA lethal dose was first determined to be 850 ± 0.2 mg/kg, i.p.. Such a dose was administered by i.p. route to a total of 90 mice divided in six circadian stages [1, 5, 9, 13, 17 and 21 Hours After Light Onset (HALO)] (15 mice/circadian time); 30 mice were used as control (5 mice / circadian time). RESULTS: The surviving treated mice exhibited a significant circadian variation in rectal temperature and body weight loss (p < 0.001). The least rectal temperature change and body weight loss occurred when VPA was injected at 9 HALO. Drug dosing at 9 HALO resulted in -9 % weight loss whereas drug dosing at 17 HALO was -15 % (Ø = 20.3 HALO ± 1.1 h, p ≤ 0.0001). Lethal toxicity also varied according to circadian dosing-time (χ(2) = 42.1, p < 0.0001). The highest (60 %) and the lowest (6.67 %) survival rates were observed at 9 HALO and 17 HALO respectively. Cosinor analyses validated a significant circadian rhythm in survival duration with an acrophase at 8.4 HALO ± 0.75 h (p < 0.001). CONCLUSIONS: With regards to these data the optimal tolerance to VPA occurred when the drug was administered in the second half of the light-rest span of mice which is physiologically analogous to the second half of the night for human patients. BioMed Central 2012-05-10 /pmc/articles/PMC3431278/ /pubmed/22574933 http://dx.doi.org/10.1186/1740-3391-10-3 Text en Copyright ©2012 Ben-Cherif et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ben-Cherif, Wafa
Dridi, Ichrak
Aouam, Karim
Ben-Attia, Mossadok
Reinberg, Alain
Boughattas, Naceur A
Chronotolerance study of the antiepileptic drug valproic acid in mice
title Chronotolerance study of the antiepileptic drug valproic acid in mice
title_full Chronotolerance study of the antiepileptic drug valproic acid in mice
title_fullStr Chronotolerance study of the antiepileptic drug valproic acid in mice
title_full_unstemmed Chronotolerance study of the antiepileptic drug valproic acid in mice
title_short Chronotolerance study of the antiepileptic drug valproic acid in mice
title_sort chronotolerance study of the antiepileptic drug valproic acid in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431278/
https://www.ncbi.nlm.nih.gov/pubmed/22574933
http://dx.doi.org/10.1186/1740-3391-10-3
work_keys_str_mv AT bencherifwafa chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice
AT dridiichrak chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice
AT aouamkarim chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice
AT benattiamossadok chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice
AT reinbergalain chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice
AT boughattasnaceura chronotolerancestudyoftheantiepilepticdrugvalproicacidinmice